Breaking News Instant updates and real-time market news.

NVS

Novartis

$87.04

2.58 (3.05%)

12:47
05/24/19
05/24
12:47
05/24/19
12:47

Novartis says wholesale acquisition cost of Zolgensma $2.125M

AveXis, a Novartis company, announced what it called "innovative access programs" for Zolgensma for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy with bi-allelic mutations in the survival motor neuron 1 gene. AveXis said it "is working closely with payers to offer pay-over-time options up to 5 years and outcomes-based agreements up to 5 years, as well as providing a patient program to support affordability and access." The wholesale acquisition cost of Zolgensma is $2.125M, which the company said is 50% of the 10-year cost of current chronic SMA treatment, estimated at $4.1M; 50% below 10-year treatment costs for genetic pediatric ultra-rare diseases, which is estimated at $4.4M-$5.7M; and 50% below the ICER ultra-rare disease cost-effectiveness threshold. Zolgensma pricing places it at approximately $250,000 per quality-adjusted life-year, the company added. "AveXis has partnered with Accredo to offer a pay-over-time option of up to 5 years to help ease possible short-term budget constraints, especially for states, small payers and self-insured employers. In addition, CuraScript SD has been selected as the sole specialty distributor given its rare disease experience, including gene and cell therapies. Reflecting the pioneering nature of these programs, more than 15 payers are in advanced discussions of terms with AveXis, with some having already agreed, in principle, to terms," the company stated following its announcement of FDA approval for Zolgensma.

  • 31

    May

NVS Novartis
$87.04

2.58 (3.05%)

05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."

TODAY'S FREE FLY STORIES

AEO

American Eagle

$17.96

0.38 (2.16%)

17:08
06/17/19
06/17
17:08
06/17/19
17:08
Conference/Events
American Eagle management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

EVOP

EVO Payments

$29.60

-0.03 (-0.10%)

17:07
06/17/19
06/17
17:07
06/17/19
17:07
Hot Stocks
EVO Payments, TouchBistro to partner on payment solutions for Mexico restaurants »

EVO Payments announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$7.19

-0.01 (-0.14%)

17:04
06/17/19
06/17
17:04
06/17/19
17:04
Hot Stocks
Ibex Investors reports 5.1% passive stake in RedHill Biopharma »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$26.23

-0.19 (-0.72%)

17:02
06/17/19
06/17
17:02
06/17/19
17:02
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics down 2.8%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$26.23

-0.19 (-0.72%)

17:01
06/17/19
06/17
17:01
06/17/19
17:01
Earnings
Steel Dynamics guides Q2 EPS 86c-90c, consensus 99c »

The company says Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$225.00

10.19 (4.74%)

, TWTR

Twitter

$36.40

0.25 (0.69%)

16:56
06/17/19
06/17
16:56
06/17/19
16:56
Hot Stocks
Tesla chief Elon Musk deletesTwitter account »

Over the weekend the…

TSLA

Tesla

$225.00

10.19 (4.74%)

TWTR

Twitter

$36.40

0.25 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

ATO

Atmos Energy

$104.66

-0.34 (-0.32%)

16:54
06/17/19
06/17
16:54
06/17/19
16:54
Conference/Events
Atmos Energy management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

TW

Tradeweb Markets

$41.77

0.33 (0.80%)

16:54
06/17/19
06/17
16:54
06/17/19
16:54
Initiation
Tradeweb Markets initiated  »

Tradeweb Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PINS

Pinterest

$27.81

0.41 (1.50%)

16:52
06/17/19
06/17
16:52
06/17/19
16:52
Initiation
Pinterest initiated  »

Wedbush starts Pinterest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

HEXO Corp

$5.50

-0.095 (-1.70%)

, TAP

Molson Coors

$53.66

-0.34 (-0.63%)

16:51
06/17/19
06/17
16:51
06/17/19
16:51
Periodicals
HEXO and Molson plan cannabis-infused drinks by December, Bloomberg says »

HEXO (HEXO) is partnering…

HEXO

HEXO Corp

$5.50

-0.095 (-1.70%)

TAP

Molson Coors

$53.66

-0.34 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 31

    Jul

CWEN

Clearway Energy

$16.31

0.205 (1.27%)

16:49
06/17/19
06/17
16:49
06/17/19
16:49
Hot Stocks
Clearway Energy announces equity commitment in repowering partnership »

Clearway Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNBT

Generex

$0.00

(0.00%)

16:46
06/17/19
06/17
16:46
06/17/19
16:46
Conference/Events
Generex to hold a conference call »

President & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$287.35

1.97 (0.69%)

16:46
06/17/19
06/17
16:46
06/17/19
16:46
Earnings
Anthem reaffirms FY19 EPS greater than $19.20, consensus $19.30 »

Officers of Anthem will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$18.95

-0.255 (-1.33%)

16:44
06/17/19
06/17
16:44
06/17/19
16:44
Initiation
Rattler Midstream initiated  »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$27.93

-0.1 (-0.36%)

16:42
06/17/19
06/17
16:42
06/17/19
16:42
Upgrade
BMO upgrades Bank of America to Outperform, sees 34% return potential »

BMO Capital analyst James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 06

    Aug

FMAO

Farmers & Merchants

$28.45

0.15 (0.53%)

16:37
06/17/19
06/17
16:37
06/17/19
16:37
Hot Stocks
Farmers & Merchants appoints Benet Rupp as CPO »

Farmers & Merchants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$27.93

-0.1 (-0.36%)

16:35
06/17/19
06/17
16:35
06/17/19
16:35
Upgrade
Bank of America rating change  »

Bank of America upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 06

    Aug

CYAD

Celyad

$13.50

-5.28 (-28.12%)

16:35
06/17/19
06/17
16:35
06/17/19
16:35
Hot Stocks
Celyad presents clinical update for CYAD-01 trials »

Celyad announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CINR

Ciner Resources

$18.87

-0.28 (-1.46%)

16:35
06/17/19
06/17
16:35
06/17/19
16:35
Hot Stocks
Ciner Resource Partners CEO Kirk Milling resigns »

On June 17, Ciner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAYF

Hudson's Bay

$0.00

(0.00%)

16:34
06/17/19
06/17
16:34
06/17/19
16:34
Hot Stocks
Hudson's Bay CFO to take medical leave of absence »

HBC announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARRY

Array BioPharma

$46.42

16.83 (56.88%)

16:34
06/17/19
06/17
16:34
06/17/19
16:34
Recommendations
Array BioPharma analyst commentary  »

Array BioPharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNTR

Venator Materials

$4.93

-0.165 (-3.24%)

16:33
06/17/19
06/17
16:33
06/17/19
16:33
Hot Stocks
Venator Materials responds to Tronox answer, counterclaims »

Venator Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

16:32
06/17/19
06/17
16:32
06/17/19
16:32
Hot Stocks
MoneyGram enters strategic partnership with Ripple »

MoneyGram announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

CAAP

Corporacion America Airport

$7.97

0.24 (3.10%)

16:32
06/17/19
06/17
16:32
06/17/19
16:32
Hot Stocks
Corporacion America Airport reports May traffic up 3.3% y/y »

Total passenger traffic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$32.71

-0.3 (-0.91%)

16:32
06/17/19
06/17
16:32
06/17/19
16:32
Hot Stocks
Synovus increases share repurchase authorization to $725M »

Synovus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.